The answer is no.
I think it's worth noting that in the CETA negotiations one of the major areas of concern has been the investment chapter, and that has been one of the major stumbling blocks, particularly in Europe, because of the potential negative consequences of it. I'm not sure why we would want to replicate that in the TPP, especially when we already know, from our own experience under a similar chapter in NAFTA, that it creates the opportunity for pharmaceutical companies to try to challenge our flexibility, in this case, patentability criteria.